![]() | |
Clinical data | |
---|---|
Trade names | Sandonorm |
Other names | LT 31-200 |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
Drug class | Beta blocker |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H28N2O3 |
Molar mass | 380.488 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Bopindolol (INN ), sold under the brand name Sandonorm among others, is a beta blocker used to treat hypertension. [1] [2] [3] [4] It has been marketed in a number of countries throughout the world, for instance in Europe. [2]
Bopindolol is an ester prodrug of mepindolol. [3] [4] It acts as a non-selective or dual β1- and β2-adrenergic receptor antagonist. [4] Bopindolol has intrinsic sympathomimetic activity (ISA) and membrane-stabilizing activity (MSA). [4] Besides the β1- and β2-adrenergic receptors, bopindolol shows very low affinity for the β3-adrenergic receptor and interacts with certain serotonin receptors such as the serotonin 5-HT1A receptor with strong affinity. [4]
The predicted log P of bopindolol ranges from 4.45 to 4.7. [5] [6] It showed the highest predicted lipophilicity of 30 clinically relevant beta blockers, with the second most lipophilic beta blocker predicted to be the better-known penbutolol. [7]
The reaction of 4-Hydroxy-2-methylindole [35320-67-3] (1) with epichlorohydrin in the presence of lye led to 2-methyl-4-(oxiran-2-ylmethoxy)-1H-indole [62119-47-5] (2). Addition of tert-butylamine led to 4-(2-Hydroxy-3-tert-butylaminopropoxy)-2-methylindole [23869-98-9] (3). Ester formation with benzoic anhydride [93-97-0] (4) in the presence of hexamethylphosphoric acid triamide [680-31-9] completed the synthesis of Bopindolol (5).
Bopindolol is related to and was developed as a successor to pindolol. [4] It was first described in the literature by at least 1977. [1]